Literature DB >> 8546142

Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis.

D O'Neal1, P Lee, B Murphy, J Best.   

Abstract

Dyslipidemia accompanies end-stage renal disease (ESRD) and contributes to the high incidence of cardiovascular disease in patients on chronic dialysis treatment. The lipid abnormalities of elevated triglyceride level and reduced high-density lipoprotein cholesterol level that occur in ESRD are associated in the normal population with an altered distribution of low-density lipoprotein (LDL) particle size, a pattern associated with increased risk of coronary heart disease. To assess the effect of ESRD on LDL particle size distribution, we examined plasma lipid levels and LDL particle size in 43 subjects on chronic hemodialysis, 23 subjects on continuous ambulatory peritoneal dialysis, and 30 control subjects with normal renal function. Of subjects on continuous ambulatory peritoneal dialysis, 48% had small LDL particle size compared with 23% of subjects on hemodialysis and 7% of control subjects. Subjects on both forms of dialysis also had higher triglyceride levels and lower high-density lipoprotein cholesterol levels that correlated with LDL particle size. We conclude that altered LDL particle size forms an important component of the metabolic abnormalities that contribute to the increased cardiovascular risk found in ESRD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8546142     DOI: 10.1016/s0272-6386(96)90034-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Effects of Ginger on Serum Lipids and Lipoproteins in Peritoneal Dialysis Patients: A Randomized Controlled Trial.

Authors:  Hadi Tabibi; Hossein Imani; Shahnaz Atabak; Iraj Najafi; Mehdi Hedayati; Leila Rahmani
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

Review 2.  Acute coronary syndromes in patients with renal disease: what are the issues?

Authors:  Carmelo J Panetta; Charles A Herzog; Timothy D Henry
Journal:  Curr Cardiol Rep       Date:  2006-07       Impact factor: 2.931

3.  Effect of dialysis membranes on lipoprotein profile of serum in haemodialysed patients.

Authors:  E Kimak; J Solski; L Janicka; B Wojtysiak; M Zagojska
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 4.  Evidence-based statin prescription for cardiovascular protection in renal impairment.

Authors:  Fabio Fabbian; Alfredo De Giorgi; Marco Pala; Ruana Tiseo; Roberto Manfredini; Francesco Portaluppi
Journal:  Clin Exp Nephrol       Date:  2011-05-10       Impact factor: 2.801

5.  Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review.

Authors:  Sahar Naderi; Joanne M Foody
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-12-20

6.  Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.

Authors:  Bengt Fellström; Faiez Zannad; Roland Schmieder; Hallvard Holdaas; Alan Jardine; Helen Rose; Wim Wilpshaar
Journal:  Curr Control Trials Cardiovasc Med       Date:  2005-05-23

7.  The lipid story in chronic kidney disease: a long story with a happy end?

Authors:  Agata Kujawa-Szewieczek; Andrzej Więcek; Grzegorz Piecha
Journal:  Int Urol Nephrol       Date:  2013-10       Impact factor: 2.370

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.